March 4, 2025 - 17:17

A recent study has revealed that the use of tocolytic drugs, which are typically administered to delay labor in cases of threatened premature birth, does not enhance the health outcomes of babies born after 30 weeks of gestation. This groundbreaking research is the largest of its kind, casting doubt on the efficacy of these contraction inhibitors in improving neonatal health.
Conducted with a significant sample size, the study tracked various health metrics and outcomes for infants whose mothers received tocolytic treatment. The findings indicated no substantial differences in health indicators between babies born to mothers who received the drugs and those who did not. This raises important questions about the necessity and effectiveness of administering tocolytics in late pregnancy.
As healthcare providers reassess the use of tocolytic drugs, this study may lead to a shift in clinical practices regarding the management of threatened preterm labor, ultimately influencing treatment guidelines and patient care strategies in obstetrics.
July 23, 2026 - 15:06
Good riddance to bundled ‘global’ maternal care billingThe American College of Obstetricians and Gynecologists is welcoming a major shift in how pregnancy and childbirth are billed. For years, the system relied on a single, bundled `global` fee that...
July 22, 2026 - 21:50
West Nile virus found in two mosquito traps in DeKalb County, health officials sayHealth authorities in DeKalb County have confirmed that mosquitoes collected from two separate traps have tested positive for the West Nile virus. The positive samples were identified during...
July 22, 2026 - 08:37
Bradford A&E services downgraded by health watchdogA health watchdog has downgraded the accident and emergency services at Bradford Royal Infirmary following an inspection that uncovered significant concerns. The Care Quality Commission (CQC) found...
July 21, 2026 - 17:42
Rare disease drugmakers try to avoid Trump price cutsPharmaceutical companies that specialize in treatments for rare diseases are scrambling to shield their products from possible price cuts under a potential second Trump administration. During his...